{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:20:27Z","timestamp":1793146827606,"version":"4.5.0"},"reference-count":41,"publisher":"American Medical Association (AMA)","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2026,6,23]]},"abstract":"\n Importance<\/jats:title>\n Adverse drug effects from blood pressure (BP)\u2013lowering drugs contribute to significant undertreatment and poor overall BP control rates.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To review adverse effects and discontinuation of BP-lowering drugs and their combinations from the 5 major classes in short-term clinical trials.<\/jats:p>\n <\/jats:sec>\n \n Data Sources and Study Selection<\/jats:title>\n Cochrane Central Register of Controlled Trials for randomized clinical trials, MEDLINE, and Epistemonikos were searched from the date of inception until December 31, 2024, for double-blind randomized clinical trials of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers (ARBs), \u03b2-blockers, calcium channel blockers (CCBs), thiazide and thiazide-like diuretics, or their combinations, with follow-up durations between 4 and 26 weeks.<\/jats:p>\n <\/jats:sec>\n \n Data Extraction and Synthesis<\/jats:title>\n Data extraction was performed by 2 independent reviewers. Synthesis was performed using fixed-effect network meta-analyses according to drug class, summarized using odds ratios (ORs) and 95% credible intervals (CrIs) and surface under the cumulative ranking curves. Final statistical analysis was conducted in April 2026.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Treatment discontinuation due to adverse events (AEs), defined as discontinuation of randomized treatment due to an AE. Secondary outcomes included headache, dizziness, edema, and cough.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 716 trials were included, with mean (SD) follow-up of 8.6 (5) weeks, including 159\u202f362 participants (mean [SD] age, 54.6 [7] years; 44% female; mean baseline BP, 158\/100 mm Hg). Compared with placebo, treatment discontinuation due to AEs was significantly increased by CCBs (OR, 1.43 [95% CrI, 1.23-1.67]; risk difference [RD], 1.2% [95% CrI, 0.6%-2.0%]), angiotensin-converting enzyme inhibitors plus CCBs (OR, 1.46 [95% CrI, 1.13-1.87]; RD, 1.1% [95% CrI, 0.2%-2.4%]), and \u03b2-blockers plus thiazide diuretics (OR, 1.58 [95% CrI, 1.04-2.47]; RD, 1.7% [95% CrI, 0.1%-4.3%]). All ARB-containing regimens had fewer treatment discontinuations due to AEs than placebo, and these differences were statistically significant for ARB monotherapy (OR, 0.73 [95% CrI, 0.61-0.86]; RD, \u22120.8% [95% CrI, \u22121.3% to \u22120.4%]) and ARBs plus CCBs (OR, 0.61 [95% CrI, 0.47-0.79]; RD, \u22121.2% [95% CrI, \u22121.8% to \u22120.6%]). In network meta-analyses, 5 combination and 2 monotherapy regimens had higher surface under the cumulative ranking curve values than placebo for treatment discontinuation due to AEs, suggesting overall symptomatic improvement compared with placebo. All regimens significantly increased dizziness, and all but CCBs significantly decreased headache compared with placebo.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This meta-analysis of short-term randomized clinical trials found that adverse drug effects that led to discontinuation of BP-lowering therapy varied by drug class and regimen, with several combination therapies being better tolerated than monotherapies. Some regimens were associated with fewer drug withdrawals than placebo, suggesting a net symptomatic improvement. These findings are based on trial-level results and rely on assumptions underlying the network meta-analysis; they may not apply to individual patients.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2026.6214","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T15:30:40Z","timestamp":1779982240000},"page":"2135","source":"Crossref","is-referenced-by-count":9,"title":["Adverse Effects and Treatment Discontinuation of Blood Pressure\u2013Lowering Drugs and Combinations"],"prefix":"10.1001","volume":"335","author":[{"given":"Nelson","family":"Wang","sequence":"first","affiliation":[{"name":"The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Van Der Hoorn","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Pant","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Kumar","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupasvi","family":"Dhurjatic","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faraidoon","family":"Haghdoost","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Abhayaratna","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Egan","sequence":"additional","affiliation":[{"name":"Improving Health Outcomes, American Medical Association, Greenville, South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aletta E.","family":"Schutte","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia"},{"name":"School of Population Health, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otavio","family":"Berwanger","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anushka","family":"Patel","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Schlaich","sequence":"additional","affiliation":[{"name":"Dobney Hypertension Centre, Medical School, Royal Perth Hospital Unit, Perth, Western Australia, Australia"},{"name":"Departments of Cardiology, Nephrology, and Transplantation, Royal Perth Hospital, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazem","family":"Rahimi","sequence":"additional","affiliation":[{"name":"Deep Medicine, Nuffield Department of Women\u2019s & Reproductive Health, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul K.","family":"Whelton","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Celia Scott Weatherhead School of Public Health & Tropical Medicine, Tulane University, New Orleans, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Rodgers","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia"},{"name":"School of Medicine, Imperial College London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Salam","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, New Delhi, India"},{"name":"Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"joi260036r1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-025-10047-1","article-title":"Factors associated with treatment intensification for uncontrolled hypertension in a US health system.","author":"An","year":"2025","journal-title":"J Gen Intern Med"},{"issue":"11","key":"joi260036r2","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.jacc.2018.07.008","article-title":"Prevention and control of hypertension: JACC Health Promotion series.","volume":"72","author":"Carey","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"joi260036r3","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1161\/HYPERTENSIONAHA.120.12858","article-title":"Starting antihypertensive drug treatment with combination therapy: controversies in hypertension\u2014con side of the argument.","volume":"77","author":"Zhang","year":"2021","journal-title":"Hypertension"},{"issue":"12","key":"joi260036r4","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.jacc.2021.07.022","article-title":"Side effect patterns in a crossover trial of statin, placebo, and no treatment.","volume":"78","author":"Howard","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"10529","key":"joi260036r5","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S0140-6736(25)01578-8","article-title":"Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials.","volume":"407","author":"Reith","year":"2026","journal-title":"Lancet"},{"issue":"12","key":"joi260036r6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0295857","article-title":"Intolerance upon statin rechallenge: a systematic review and meta-analysis of randomized controlled trials.","volume":"18","author":"Kraut","year":"2023","journal-title":"PLoS One"},{"issue":"6","key":"joi260036r7","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1097\/HJH.0000000000002785","article-title":"Blood pressure control in Australian general practice: analysis using general practice records of 1.2 million patients from the MedicineInsight database.","volume":"39","author":"Roseleur","year":"2021","journal-title":"J Hypertens"},{"issue":"11","key":"joi260036r8","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1001\/jamacardio.2020.2739","article-title":"Association of low-dose triple combination therapy with therapeutic inertia and prescribing patterns in patients with hypertension: a secondary analysis of the TRIUMPH trial.","volume":"5","author":"Wang","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"5","key":"joi260036r9","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1161\/HYPERTENSIONAHA.123.22284","article-title":"Therapeutic inertia with initial low-dose quadruple combination therapy for hypertension: results from the QUARTET trial.","volume":"81","author":"Wang","year":"2024","journal-title":"Hypertension"},{"issue":"6","key":"joi260036r10","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1097\/HJH.0000000000001287","article-title":"Side effects and tolerability of combination blood pressure lowering according to blood pressure levels: an analysis of the PROGRESS and ADVANCE trials.","volume":"35","author":"Atkins","year":"2017","journal-title":"J Hypertens"},{"issue":"7404","key":"joi260036r11","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1136\/bmj.326.7404.1427","article-title":"Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials.","volume":"326","author":"Law","year":"2003","journal-title":"BMJ"},{"issue":"8","key":"joi260036r12","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1592\/phco.21.11.940.34520","article-title":"Discontinuation of antihypertensive drugs due to adverse events: a systematic review and meta-analysis.","volume":"21","author":"Ross","year":"2001","journal-title":"Pharmacotherapy"},{"issue":"11","key":"joi260036r13","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008170.pub3","article-title":"First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.","volume":"11","author":"Chen","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"joi260036r14","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008161.pub3","article-title":"First-line diuretics versus other classes of antihypertensive drugs for hypertension.","volume":"7","author":"Reinhart","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"joi260036r16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"joi260036r17","doi-asserted-by":"publisher","DOI":"10.2196\/65205","article-title":"Development of the Double-blind, Randomised Trials of Effects of Antihypertensive Medicines (DREAM) database and characteristics of the included trials: protocol for an umbrella review and meta-analyses.","volume":"14","author":"Salam","year":"2025","journal-title":"JMIR Res Protoc"},{"issue":"5","key":"joi260036r19","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1177\/0272989X12458724","article-title":"Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials.","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Making"},{"key":"joi260036r20","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1177\/0272989X13485156","article-title":"NICE DSU technical support document 7: evidence synthesis of treatment efficacy in decision making: a reviewer\u2019s checklist.","volume":"33","author":"Ades","year":"2013","journal-title":"Med Decis Making"},{"issue":"2","key":"joi260036r22","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1177\/1740774513498322","article-title":"Network meta-analysis of randomized clinical trials: reporting the proper summaries.","volume":"11","author":"Zhang","year":"2014","journal-title":"Clin Trials"},{"issue":"15","key":"joi260036r34","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1161\/CIRCULATIONAHA.104.529628","article-title":"Headaches and the treatment of blood pressure: results from a meta-analysis of 94 randomized placebo-controlled trials with 24,000 participants.","volume":"112","author":"Law","year":"2005","journal-title":"Circulation"},{"issue":"2","key":"joi260036r35","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1365-2125.2006.02751.x","article-title":"Calcium channel blockers and headache.","volume":"63","author":"Law","year":"2007","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"joi260036r36","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1177\/0004867417721654","article-title":"Blockade of the angiotensin system improves mental health domain of quality of life: a meta-analysis of randomized clinical trials.","volume":"52","author":"Brownstein","year":"2018","journal-title":"Aust N Z J Psychiatry"},{"issue":"6","key":"joi260036r37","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3109\/08037059709062095","article-title":"Does lowering the blood pressure improve the mood? quality-of-life results from the Hypertension Optimal Treatment (HOT) study.","volume":"6","author":"Wiklund","year":"1997","journal-title":"Blood Press"},{"issue":"4","key":"joi260036r38","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003822.pub2","article-title":"Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension.","volume":"2008","author":"Heran","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"joi260036r39","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1097\/HJH.0000000000001052","article-title":"Effects of blood-pressure-lowering treatment in hypertension: 9. discontinuations for adverse events attributed to different classes of antihypertensive drugs: meta-analyses of randomized trials.","volume":"34","author":"Thomopoulos","year":"2016","journal-title":"J Hypertens"},{"key":"joi260036r40","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103696","article-title":"Persistence to antihypertensive drug classes in uncomplicated hypertension: a nationwide Swedish cohort study.","volume":"91","author":"Laurell","year":"2025","journal-title":"eClinicalMedicine"},{"issue":"12","key":"joi260036r41","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1007\/s11255-018-1991-x","article-title":"The benefits of angiotensin-converting enzyme inhibitors\/angiotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: a meta-analysis.","volume":"50","author":"Pongpanich","year":"2018","journal-title":"Int Urol Nephrol"},{"key":"joi260036r15","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"key":"joi260036r21","volume-title":"Oxford Textbook of Medicine","author":"Baigent","year":"2010"},{"key":"joi260036r18","unstructured":"Phillippo? DM. multinma: bayesian network meta-analysis of individual and aggregate data. Zenodo. August 29, 2022. Accessed October 1, 2022. https:\/\/zenodo.org\/record\/7033094#.Y8bhAHb7Q2w"},{"key":"joi260036r23","unstructured":"AstraZeneca. Atacand (candesartan cilexetil) tablets. 2005. Accessed April 9, 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2005\/020838s022lbl.pdf"},{"key":"joi260036r24","unstructured":"Boehringer Ingelheim. Telmisartan (Micardis) and amlodipine (Norvasc)\u2014factorial design study for the treatment of hypertension. Updated March 27, 2014. Accessed April 9, 2026. https:\/\/clinicaltrials.gov\/study\/NCT00281580"},{"key":"joi260036r25","unstructured":"Boehringer Ingelheim. Micardis (telmisartan) tablets. 2011. Accessed April 9, 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020850s032lbl.pdf"},{"key":"joi260036r26","unstructured":"Daiichi Sankyo. Benicar (olmesartan medoxomil) tablets. 2012. Accessed April 9, 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021286s023lbl.pdf"},{"key":"joi260036r27","unstructured":"US Food and Drug Administration. Micardis (telmisartan) tablets. 1998. Accessed April 9, 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020850s032lbl.pdf"},{"key":"joi260036r28","unstructured":"US Food and Drug Administration. Atacand (candesartan cilexetil) tablets. 2001. Accessed April 9, 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2006\/020838s026lbl.pdf"},{"key":"joi260036r29","unstructured":"US Food and Drug Administration. Diovan (valsartan) tablets. 2001. Accessed April 9, 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021283s033lbl.pdf"},{"key":"joi260036r30","unstructured":"US Food and Drug Administration. Benicar (olmesartan medoxomil) tablets. 2002. Accessed April 9, 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021286s023lbl.pdf"},{"key":"joi260036r31","unstructured":"US Food and Drug Administration. Exforge (amlodipine and valsartan) tablets. 2007. Accessed April 9, 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021990s016lbl.pdf"},{"key":"joi260036r32","unstructured":"US Food and Drug Administration. Azor (amlodipine besylate and olmesartan medoxomil) tablets. 2007. Accessed April 9, 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/022100s033lbl.pdf"},{"key":"joi260036r33","unstructured":"US Food and Drug Administration. Exforge HCT (amlodipine, valsartan, and hydrochlorothiazide) tablets. 2009. Accessed April 9, 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/022314s013lbl.pdf"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2849512\/jama_wang_2026_oi_260036_1781550118.8298.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:34:01Z","timestamp":1782228841000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2849512"}},"subtitle":["A Network Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":41,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2026,6,23]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2026.6214","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,23]]}}}